Evidence map›Paper›PMID 26313909›Full record

ArticlePloS one2015

High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.

Christopher Ullman, Pascale Mathonet, Arkadiusz Oleksy, Agata Diamandakis, Licia Tomei, Anna Demartis, Chiara Nardi, Sonia Sambucini, Antonino Missineo, Karen Alt and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. [Npj imaging · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Engineered Autonomous Human Variable Domains.Current pharmaceutical design · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Christopher UllmanIsogenica, Ltd. Cambridge, United Kingdom.
Pascale MathonetIsogenica, Ltd. Cambridge, United Kingdom.
Arkadiusz OleksyIsogenica, Ltd. Cambridge, United Kingdom.
Agata DiamandakisIsogenica, Ltd. Cambridge, United Kingdom.
Licia TomeiIRBM Science Park, Rome, Italy.
Anna DemartisIRBM Science Park, Rome, Italy.
Chiara NardiIRBM Science Park, Rome, Italy.
Sonia SambuciniIRBM Science Park, Rome, Italy.
Antonino MissineoIRBM Science Park, Rome, Italy.
Karen AltVascular Biotechnology, Baker IDI, Melbourne, Australia.
Christoph E HagemeyerVascular Biotechnology, Baker IDI, Melbourne, Australia.
Matt HarrisClarity Pharmaceuticals, Ltd. Sydney, Australia.
Amos HedtClarity Pharmaceuticals, Ltd. Sydney, Australia.
Roland WeisVTU Technology, Grambach, Austria.
Kurt R GehlsenResearch Corporation Technologies, Inc. Tucson, Arizona, United States of America.
IRBM Science Park · ITBaker Heart and Diabetes Institute · AUResearch Corporation Technologies (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abdurins are a novel antibody-like scaffold derived from the engineering of a single isolated CH2 domain of human IgG. Previous studies established the prolonged serum half-life of Abdurins, the result of a retained FcRn binding motif. Here we present data on the construction of large, diverse, phage-display and cell-free DNA display libraries and the isolation of high affinity binders to the cancer target, membrane-bound ephrin receptor tyrosine kinase class A2 (EphA2). Antigen binding regions were created by designing combinatorial libraries into the structural loops and Abdurins were selected using phage display methods. Initial binders were reformatted into new maturation libraries and low nanomolar binders were isolated using cell-free DNA display, CIS display. Further characterization confirmed binding of the Abdurins to both human and murine EphA2 proteins and exclusively to cell lines that expressed EphA2, followed by rapid internalization. Two different EphA2 binders were labeled with 64Cu, using a bifunctional MeCOSar chelator, and administered to mice bearing tumors from transplanted human prostate cancer cells, followed by PET/CT imaging. The anti-EphA2 Abdurins localized in the tumors as early as 4 hours after injection and continued to accumulate up to 48 hours when the imaging was completed. These data demonstrate the ability to isolate high affinity binders from the engineered Abdurin scaffold, which retain a long serum half-life, and specifically target tumors in a xenograft model.

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorHumansMicePeptide LibraryPositron-Emission TomographyProtein EngineeringReceptor, EphA2Tomography, X-Ray ComputedXenograft Model Antitumor AssaysAntineoplastic AgentsPeptide LibraryReceptor, EphA2

Identifiers

PMID26313909
PMCPMC4552014
OpenAlexW2150053749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.